Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.

Key facts

Study ID

NCT00466921

Run by

Northwestern University

People needed

33

Starts

2005-04-19

Expected to finish

2013-05-17

Last updated by the study team

2020-12-01

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford Cancer Center — Stanford, California, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.